Dexamethasone and lenvatinib inhibit migration and invasion of non‑small cell lung cancer by regulating EKR/AKT and VEGF signal pathways

Zhang,Daye; Zhang,Yongxiang; Cai,Zeyuan; Tu,Ying; Hu,Zhansong

doi:10.3892/etm.2019.8225

Dexamethasone and lenvatinib inhibit migration and invasion of non‑small cell lung cancer by regulating EKR/AKT and VEGF signal pathways

Authors:
- Daye Zhang
- Yongxiang Zhang
- Zeyuan Cai
- Ying Tu
- Zhansong Hu
View Affiliations

Affiliations: Department of Pharmacy, Tianjin Chest Hospital, Tianjin 300222, P.R. China, Respiratory and Clinical Care Unit, Tianjin Chest Hospital, Tianjin 300222, P.R. China, Department of Cardiovascular Institute, Tianjin Chest Hospital, Tianjin 300222, P.R. China
Published online on: November 21, 2019 https://doi.org/10.3892/etm.2019.8225
Pages: 762-770

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Migration and invasion is one of the most important features in tumor metastasis and development. Non‑small cell lung cancer (NSCLC) is one of the most common types of cancer globally, and has been linked to air contamination. Evidence indicates that cysteine‑rich angiogenic inducer 61 (CYR61) is associated with the migration and invasion of NSCLC. Overexpression of CYR61 protein promotes the migration and the transition of tumor‑derived vascular endothelial cells in NSCLC. However, the association between CYR61 and NSCLC remains poorly understood. Lenvatinib is an oral multi‑target drug that targets various receptors upon tumor angiogenesis. Dexamethasone is widely approved for combination therapy in patients with NSCLC. In the current study, the expression and function of CYR61 in NSCLC was analyzed during the progression of NSCLC. Inhibitory effects on migration and invasion induced by lenvatinib and dexamethasone were determined by migratory and invasion assays. Migratory pathways of extracellular signal‑regulated kinases (ERK) and protein kinase B (AKT) were also investigated by targeting vascular endothelial growth factor (VEGF) and CYR61 via synergistic treatment with transforming growth factor‑β1 (TGF‑β1) and dexamethasone. Therapeutic outcomes of combined treatment with lenvatinib and dexamethasone were assessed in NSCLC‑bearing mice. The results of the present study indicate that cooperative treatment of lenvatinib and dexamethasone significantly inhibited TGF‑β1‑induced cell migration and suppressed tumor growth (P<0.01). Notably, the results demonstrated that dexamethasone eradicated the promotion effects of TGF‑β1 on the AKT/epithelial‑mesenchymal transition process and lenvatinib extinguished tumor cell metastasis by targeting VEGF. The results of the current study also demonstrate that dexamethasone suppressed the expression of CAG‑I and enhanced expression of matrix metalloproteinase‑1. Synergistic treatment for NSCLC was demonstrated to be efficacious. In conclusion, dexamethasone inhibited AKT/ERK phosphorylation and lenvatinib antagonism bound VEGF leading to the limitation of migration and invasion of cancer cells in NSCLC.

View Figures

View References

1	Fenton-Ambrose L and Kazerooni EA: Preventative care: Lung-cancer screens now worth the cost. Nature. 514:352014. View Article : Google Scholar : PubMed/NCBI
2	Kong R, Feng J, Ma Y, Zhou B, Li S, Zhang W, Jiang J, Zhang J, Qiao Z, Zhang T, et al: Silencing NACK by siRNA inhibits tumorigenesis in non-small cell lung cancer via targeting Notch1 signaling pathway. Oncol Rep. 35:2306–2314. 2016. View Article : Google Scholar : PubMed/NCBI
3	Brody H: Lung cancer. Nature. 513:S12014. View Article : Google Scholar : PubMed/NCBI
4	Moro-Sibilot D, Smit E, de Castro Carpeño J, Lesniewski-Kmak K, Aerts JG, Villatoro R, Kraaij K, Nacerddine K, Dyachkova Y, Smith KT, et al: Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study. Lung Cancer. 90:427–432. 2015. View Article : Google Scholar : PubMed/NCBI
5	Barnett SA, Downey RJ, Zheng J, Plourde G, Shen R, Chaft J, Akhurst T, Park BJ and Rusch VW: Utility of routine PET imaging to predict response and survival after induction therapy for non-small cell lung cancer. Ann Thorac Surg. 101:1052–1059. 2016. View Article : Google Scholar : PubMed/NCBI
6	Xie FJ, Lu HY, Zheng QQ, Qin J, Gao Y, Zhang YP, Hu X and Mao WM: The clinical pathological characteristics and prognosis of FGFR1 gene amplification in non-small-cell lung cancer: A meta-analysis. Onco Targets Ther. 9:171–181. 2016. View Article : Google Scholar : PubMed/NCBI
7	Lim SH, Sun JM, Lee SH, Ahn JS, Park K and Ahn MJ: Pembrolizumab for the treatment of non-small cell lung cancer. Expert Opin Biol Ther. 16:397–406. 2016. View Article : Google Scholar : PubMed/NCBI
8	Müller B, Bovet M, Yin Y, Stichel D, Malz M, González-Vallinas M, Middleton A, Ehemann V, Schmitt J, Muley T, et al: Concomitant expression of far upstream element (FUSE) binding protein (FBP) interacting repressor (FIR) and its splice variants induce migration and invasion of non-small cell lung cancer (NSCLC) cells. J Pathol. 237:390–401. 2015. View Article : Google Scholar : PubMed/NCBI
9	Zhao Q, Yue J, Zhang C, Gu X, Chen H and Xu L: Inactivation of M2 AChR/NF-κB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC). Oncotarget. 6:29335–29346. 2015. View Article : Google Scholar : PubMed/NCBI
10	Zhang H, Zhu X, Li N, Li D, Sha Z, Zheng X and Wang H: miR-125a-3p targets MTA1 to suppress NSCLC cell proliferation, migration, and invasion. Acta Biochim Biophys Sin (Shanghai). 47:496–503. 2015. View Article : Google Scholar : PubMed/NCBI
11	Roth MT, Ivey JL, Esserman DA, Crisp G, Kurz J and Weinberger M: Individualized medication assessment and planning: Optimizing medication use in older adults in the primary care setting. Pharmacotherapy. 33:787–797. 2013. View Article : Google Scholar : PubMed/NCBI
12	Solimando DA Jr and Waddell JA: Lenvatinib and palbociclib. Hosp Pharm. 50:578–582. 2015. View Article : Google Scholar : PubMed/NCBI
13	Oikonomopoulos G, Aravind P and Sarker D: Lenvatinib: A potential breakthrough in advanced hepatocellular carcinoma? Future Oncol. 12:465–476. 2016. View Article : Google Scholar : PubMed/NCBI
14	Nishio M, Horai T, Horiike A, Nokihara H, Yamamoto N, Takahashi T, Murakami H, Yamamoto N, Koizumi F, Nishio K, et al: Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer. Br J Cancer. 109:538–544. 2013. View Article : Google Scholar : PubMed/NCBI
15	Hutson TE: Targeted therapies for the treatment of metastatic renal cell carcinoma: Clinical evidence. Oncologist. 16 (Suppl 2):S14–S22. 2011. View Article : Google Scholar
16	Matsui J and Funahashi Y: Preclinical biomarker research and patient stratification of molecular target agents: The anti-angiogenic inhibitor Lenvatinib mesylate (E7080). Nihon Yakurigaku Zasshi. 142:162–166. 2013. View Article : Google Scholar : PubMed/NCBI
17	Okamoto K, Kodama K, Takase K, Sugi NH, Yamamoto Y, Iwata M and Tsuruoka A: Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 340:97–103. 2013. View Article : Google Scholar : PubMed/NCBI
18	Kuznar W: Lenvatinib extends survival in metastatic renal-cell carcinoma. Am Health Drug Benefits. 8:182015.(In Japanese). PubMed/NCBI
19	Molina AM, Hutson TE, Larkin J, Gold AM, Wood K, Carter D, Motzer R and Michaelson MD: A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer Chemother Pharmacol. 73:181–189. 2014. View Article : Google Scholar : PubMed/NCBI
20	Berdeja J, Jagannath S, Zonder J, Badros A, Kaufman JL, Manges R, Gupta M, Tendolkar A, Lynch M, Bleickardt E, et al: Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: Results of a phase Ib study. Clin Lymphoma Myeloma Leuk. 16:129–138. 2016. View Article : Google Scholar : PubMed/NCBI
21	Han S, Bui NT, Ho MT, Kim YM, Cho M and Shin DB: Dexamethasone inhibits TGF-β1-induced cell migration by regulating the ERK and AKT pathways in human colon cancer cells via CYR61. Cancer Res Treat. 48:1141–1153. 2016. View Article : Google Scholar : PubMed/NCBI
22	Chijiiwa M, Mochizuki S, Kimura T, Abe H, Tanaka Y, Fujii Y, Shimizu H, Enomoto H, Toyama Y and Okada Y: CCN1 (Cyr61) is overexpressed in human osteoarthritic cartilage and inhibits ADAMTS-4 (Aggrecanase 1) activity. Arthritis Rheumatol. 67:1557–1567. 2015. View Article : Google Scholar : PubMed/NCBI
23	Grazioli S, Gil S, An D, Kajikawa O, Farnand AW, Hanson JF, Birkland T, Chen P, Duffield J, Schnapp LM, et al: CYR61 (CCN1) overexpression induces lung injury in mice. Am J Physiol Lung Cell Mol Physiol. 308:L759–L765. 2015. View Article : Google Scholar : PubMed/NCBI
24	Zhuang T, Djemil T, Qi P, Magnelli A, Stephans K, Videtic G and Xia P: Dose calculation differences between Monte Carlo and pencil beam depend on the tumor locations and volumes for lung stereotactic body radiation therapy. J Appl Clin Med Phys. 14:40112013. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Huang YT, Lan Q, Ponsonnet L, Blanquet M, Christofori G, Zaric J and Rüegg C: The matricellular protein CYR61 interferes with normal pancreatic islets architecture and promotes pancreatic neuroendocrine tumor progression. Oncotarget. 7:1663–1674. 2016.PubMed/NCBI
27	Nagashima S, Matsuo S, Takahashi M, Umemoto Y, Hirano T, Enomoto K, Sakurai K and Amano S: Effectiveness of lenvatinib for thyroid cancer with lung metastases-report of a case. Gan To Kagaku Ryoho. 43:2121–2123. 2016.(In Japanese). PubMed/NCBI
28	Li Z, Xu X, Bai L, Chen W and Lin Y: Epidermal growth factor receptor-mediated tissue transglutaminase overexpression couples acquired tumor necrosis factor-related apoptosis-inducing ligand resistance and migration through c-FLIP and MMP-9 proteins in lung cancer cells. J Biol Chem. 286:21164–21172. 2011. View Article : Google Scholar : PubMed/NCBI
29	Lee YT, Liu CJ, Hu YW, Teng CJ, Tzeng CH, Yeh CM, Chen TJ, Lin JK, Lin CC, Lan YT, et al: Incidence of second primary malignancies following colorectal cancer: A distinct pattern of occurrence between colon and rectal cancers and association of co-morbidity with second primary malignancies in a population-based cohort of 98,876 patients in Taiwan. Medicine (Baltimore). 94:e10792015. View Article : Google Scholar : PubMed/NCBI
30	Charvat H, Sasazuki S, Inoue M, Iwasaki M, Sawada N, Shimazu T, Yamaji T and Tsugane S; JPHC Study Group, : Prediction of the 10-year probability of gastric cancer occurrence in the Japanese population: The JPHC study cohort II. Int J Cancer. 138:320–331. 2016. View Article : Google Scholar : PubMed/NCBI
31	Kim DS, Park KM, Won YS, Kim JY, Lee JK, Kim JG, Oh ST, Jung SS and Kang WK: Occurrence and prognosis of symptomatic venous thromboembolism in colorectal cancer surgery patients. Vasc Specialist Int. 30:49–55. 2014. View Article : Google Scholar : PubMed/NCBI
32	Gold M, Dunn LB, Phoenix B, Paul SM, Hamolsky D, Levine JD and Miaskowski C: Co-occurrence of anxiety and depressive symptoms following breast cancer surgery and its impact on quality of life. Eur J Oncol Nurs. 20:97–105. 2016. View Article : Google Scholar : PubMed/NCBI
33	Zhu X, Song Y, Huo R, Zhang J, Sun S, He Y, Gao H, Zhang M, Sun X, Zhai T, et al: Cyr61 participates in the pathogenesis of rheumatoid arthritis by promoting proIL-1β production by fibroblast-like synoviocytes through an AKT-dependent NF-κB signaling pathway. Clin Immunol. 157:187–197. 2015. View Article : Google Scholar : PubMed/NCBI
34	Sánchez-Bailón MP, Calcabrini A, Mayoral-Varo V, Molinari A, Wagner KU, Losada JP, Ciordia S, Albar JP and Martín-Pérez J: Cyr61 as mediator of Src signaling in triple negative breast cancer cells. Oncotarget. 6:13520–13538. 2015. View Article : Google Scholar : PubMed/NCBI
35	Lee YJ, Lee DM and Lee SH: Production of Cyr61 protein is modulated by extracellular acidification and PI3K/Akt signaling in prostate carcinoma PC-3 cells. Food Chem Toxicol. 58:169–176. 2013. View Article : Google Scholar : PubMed/NCBI
36	Chen J, Song Y, Yang J, Gong L, Zhao P, Zhang Y and Su H: The up-regulation of cysteine-rich protein 61 induced by transforming growth factor beta enhances osteosarcoma cell migration. Mol Cell Biochem. 384:269–277. 2013. View Article : Google Scholar : PubMed/NCBI
37	Villanueva MT: Targeted therapies: Congratulations, you are still in the running towards becoming ovarian-next-top treatment. Nat Rev Clin Oncol. 8:5702011. View Article : Google Scholar : PubMed/NCBI
38	Ngeow J, Tan IB and Choo SP: Targeted therapies in the treatment of gastric cancer. Asia Pac J Clin Oncol. 7:224–235. 2011. View Article : Google Scholar : PubMed/NCBI
39	Boss DS, Glen H, Beijnen JH, Keesen M, Morrison R, Tait B, Copalu W, Mazur A, Wanders J, O'Brien JP, et al: A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer. 106:1598–1604. 2012. View Article : Google Scholar : PubMed/NCBI
40	Tsuruoka A, Matsui J, Suzuki T, Koyama N, Watanabe T and Funahashi Y: Preclinical and clinical researches of lenvatinib mesylate (Lenvima capsule), a novel antitumor agent approved for thyroid cancer treatment. Nihon Yakurigaku Zasshi. 146:283–290. 2015.(In Japanese). View Article : Google Scholar : PubMed/NCBI
41	Nakagawa T, Matsushima T, Kawano S, Nakazawa Y, Kato Y, Adachi Y, Abe T, Semba T, Yokoi A, Matsui J, et al: Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor. Cancer Sci. 105:723–730. 2014. View Article : Google Scholar : PubMed/NCBI